<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004077</url>
  </required_header>
  <id_info>
    <org_study_id>67919</org_study_id>
    <nct_id>NCT05004077</nct_id>
  </id_info>
  <brief_title>Repeated Amiodarone Dosing In Cardiac surgicaL Procedures</brief_title>
  <acronym>RADICAL</acronym>
  <official_title>Repeated Amiodarone Dosing In Cardiac surgicaL Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kevin Hatton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, prospective, randomized, open-label trial of subjects who&#xD;
      develop atrial fibrillation after non-emergent cardiac surgery at the University of Kentucky&#xD;
      Chandler Medical Center (UKCMC). Patients will be randomized to receive either a conventional&#xD;
      amiodarone dosing regimen (CDR) or a repeated amiodarone bolus dosing regimen (RBDR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will screen and consent approximately 150 patients undergoing non-emergent cardiac&#xD;
      surgery. Approximately 60 of these patients are likely to develop stable postoperative atrial&#xD;
      fibrillation (POAF) in the postoperative period. Amiodarone is commonly given as an initial&#xD;
      intravenous (IV) bolus (150 mg IV) followed by a combined IV and oral load to a total dose of&#xD;
      8 gm. Because of amiodarone's beta-blocker activity, the IV bolus in patients with POAF is&#xD;
      associated with a reduced heart rate that may lead to restoration of NSR. For this reason,&#xD;
      some clinicians will provide up to 5 additional IV amiodarone boluses during the drug's&#xD;
      loading period to treat RVR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normal Sinus Rhythm -24 HRS</measure>
    <time_frame>24-hours after receiving amiodarone bolus</time_frame>
    <description>Percentage of patients who develop stable POAF after non-emergent cardiac surgery, the percentage of patients who have converted to NSR at 24-hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have converted to NSR after a conventional amiodarone IV loading dose regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Target Heart Rate Time</measure>
    <time_frame>24-hours after receiving amiodarone bolus</time_frame>
    <description>Total time, in minutes, during the first 24 hours that the patient achieves target HR (HR &lt; 110 bpm) between patients who receive a repeated amiodarone bolus dosing regimen and those who receive a conventional amiodarone bolus dosing regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Target Heart Rate</measure>
    <time_frame>24-hours after receiving amiodarone bolus</time_frame>
    <description>Time to achieve target HR (HR &lt; 110 bpm) between patients who receive a repeated amiodarone bolus dosing regimen and those who receive a conventional amiodarone bolus dosing regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal Sinus Rhythm -Hospital Index</measure>
    <time_frame>duration of ICU and hospital visit, up to 20 days</time_frame>
    <description>Percentage of patients who achieve NSR by ICU discharge and hospital discharge between patients who receive a repeated amiodarone bolus dosing regimen and those who receive a conventional amiodarone bolus dosing regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent AF</measure>
    <time_frame>duration of ICU and hospital visit, up to 20 days</time_frame>
    <description>Percentage of patients who have recurrent AF before ICU discharge and before hospital discharge and patients who receive a repeated amiodarone bolus dosing regimen and those who receive a conventional amiodarone bolus dosing regimen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Conventional amiodarone dosing regimen (CDR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial amiodarone bolus of 150 mg IV over 10 minutes then a 24-hour amiodarone loading infusion (1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours), followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeated amiodarone bolus dosing regimen (RBDR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial amiodarone bolus of 150 mg IV over 10 minutes, then 1.0 mg/min IV amiodarone infusion for 6 hours, then a 0.5 mg/min IV amiodarone infusion for 18 hours, followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. In addition, patients in the RBDR will receive an additional 150 mg IV amiodarone bolus whenever the patient develops tachycardia (Heart Rate (HR) = 110 beats per minute) lasting more than 10 minutes. This bolus may be repeated up to a total of 5 times (6 total boluses) over the first 24 hours. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMIODARONE</intervention_name>
    <description>Assess the effectiveness of different dosing strategies of amiodarone.</description>
    <arm_group_label>Conventional amiodarone dosing regimen (CDR)</arm_group_label>
    <arm_group_label>Repeated amiodarone bolus dosing regimen (RBDR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be 18 years old or older&#xD;
&#xD;
          -  Subject must be willing to give written informed consent&#xD;
&#xD;
          -  Subject must undergo or scheduled for non-emergent cardiac surgery, including coronary&#xD;
             artery bypass grafting (CABG), non-infectious valve repair or replacement, atrial or&#xD;
             septal defect repair, thoracic aortic replacement surgery, or any combination of these&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented allergy to amiodarone or iodine&#xD;
&#xD;
          -  History of atrial fibrillation or other heart conduction system abnormality&#xD;
&#xD;
          -  History of cardiac maze, pulmonary vein isolation, or other procedure affecting the&#xD;
             conduction system&#xD;
&#xD;
          -  Scheduled cardiac maze, pulmonary vein isolation, or other procedure affecting the&#xD;
             conduction system&#xD;
&#xD;
          -  Low cardiac index or cardiogenic shock requiring pharmacologic or mechanical support&#xD;
&#xD;
          -  History of pre-existing respiratory system disease requiring oxygen therapy prior to&#xD;
             admission&#xD;
&#xD;
          -  History of cirrhosis or other chronic liver diseases&#xD;
&#xD;
          -  Pregnancy or breastfeeding mothers&#xD;
&#xD;
          -  Prisoner status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Hatton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Hatton, MD</last_name>
    <phone>8592180365</phone>
    <email>kevin.hatton@uky.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Banfield, MA</last_name>
    <phone>8592180365</phone>
    <email>a.banfield@uky.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Hatton, MD</last_name>
      <phone>859-323-5956</phone>
      <email>kevin.hatton@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Banfield, MA</last_name>
      <phone>859-218-0365</phone>
      <email>a.banfield@uky.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Kevin Hatton</investigator_full_name>
    <investigator_title>Professor, Dept of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

